Drugs / DSB2455
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06458712 | Nov 2024 → Aug 2028 expected | neoplastic disease or syndrome | Duke Street Bio Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-16 | Duke Street Bio Ltd | Regulatory Duke Street Bio Receives FDA Fast Track Designation for PARP1-Selective Inhibitor DSB2455 dukestbio.com ↗
Duke Street Bio, a clinical-stage biotechnology company focused on precision oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DSB2455 |
| 2024-09-24 | Duke Street Bio Ltd | Regulatory Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial dukestbio.com ↗
Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-16 | Duke Street Bio Ltd | Duke Street Bio Receives FDA Fast Track Designation for PARP1-Selective Inhibitor DSB2455 dukestbio.com ↗ |
| 2024-12-02 | Duke Street Bio Ltd | Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours dukestbio.com ↗ |
| 2024-09-24 | Duke Street Bio Ltd | Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial dukestbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSB2455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06458712 ↗ |
| Action | Inhibit | “PARP1 selective inhibitor” NCT06458712 ↗ |
| Target | PARP1 | “PARP1 selective inhibitor” NCT06458712 ↗ |